Your session is about to expire
← Back to Search
Study Summary
"This trial aims to test if MK-1167 is safe and effective for patients with Alzheimer's Disease who are already taking Donepezil."
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there an age restriction for participation in this medical study, specifically with respect to individuals older than 25 years?
"To be eligible for this research study, individuals must fall within the age bracket of 50 to 90 years. Notably, there are no less than 14 trials tailored for patients below 18 and a substantial number of 523 studies focused on those above the age of consent."
What is the current number of subjects participating in this medical research study?
"The details on clinicaltrials.gov confirm that this medical investigation is actively seeking candidates. Initially listed on March 28, 2024, the trial's most recent update was on April 2, 2024. A total of 16 participants are sought from three distinct sites."
Which specific criteria must individuals meet in order to qualify as potential participants for this research study?
"The research aims to recruit 16 individuals aged between 50 and 90 who have been diagnosed with Alzheimer's disease. Eligible participants must demonstrate a history of cognitive and functional decline that has developed gradually over the course of at least one year before the screening process. This decline should either be confirmed by an individual familiar with the patient or documented in their medical records. Moreover, candidates need to meet the diagnostic criteria for probable Alzheimer's disease according to guidelines established by both NINCDS-ADRDA. Additionally, they are required to have a dependable caregiver who maintains close contact with them at least three days per week for a minimum of six waking"
What are the main goals that this investigation aims to achieve?
"During the study period lasting approximately 3 weeks, the primary goal is to track and document any Adverse Events (AE) experienced by participants. Secondary measures will include assessing Oral Clearance (CL/F) of MK-1167 from Plasma, denoting how swiftly MK-6552 is eliminated from plasma; Plasma Concentration at 24 hours postdose (C24), reflecting levels of MK-1167 in plasma after a specified timeframe; and Time to Reach Maximum Plasma Concentration (Tmax) of MK-1167, indicating how quickly maximum drug concentration in plasma is achieved following dosing."
Are there still available openings for new participants in this research study?
"Indeed, the details on clinicaltrials.gov specify that patient recruitment is ongoing for this investigation. This trial was initially uploaded on March 28th, 2024 and last revised on April 2nd, 2024. The aim is to enroll a total of 16 participants from three distinct sites."
Has the Food and Drug Administration given their approval for MK-1167?
"Given the early stage of this trial, with limited data available to support safety and efficacy, MK-1167 has been rated as a 1 on our safety scale."
Share this study with friends
Copy Link
Messenger